Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients

Drugs in Context

article

Margarida Gonçalo¹  Maria João Paiva Lopes²  Alberto Mota⁴  Tiago Torres⁶  Cristina Claro⁸  Leonor Ramos¹  Manuela Selores⁶  Pedro Mendes Bastos⁹  Joana Rocha^1,10  Rodrigo Carvalho²  Paulo Filipe^1,11 

[1] Department of Dermatology, University Hospital and Faculty of Medicine, University of Coimbra;Department of Dermatology, Centro Hospitalar Universitário de Lisboa Central;CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa;Department of Dermatovenereology, Centro Hospitalar Universitário de São João EPE;Faculty of Medicine, Porto University;Department of Dermatology, Centro Hospitalar Universitário do Porto;Instituto de Ciências Biomédicas Abel Salazar, University of Porto;Dermatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental;Hospital CUF Descobertas;Department of Dermatology, Hospital de Pedro Hispano;Department of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte;Faculty of Medicine, University of Lisbon;Dermatology Research Unit, iMM João Lobo Antunes, University of Lisbon

关键词: atopic dermatitis;    biologic therapy;    guidelines;    JAK inhibitors;    recommendations;   

DOI  :  10.7573/dic.2021-9-5

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

Atopic dermatitis is a highly prevalent chronic, immune-mediated inflammatory skin disease with a significant burden on patients, families and healthcare systems. This article presents recommendations developed by the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology addressing several clinical questions that arise in the management and care of moderate-to-severe atopic dermatitis with biologic agents and Janus kinase (JAK) inhibitors based on the available evidence. The recommendations were generated after a thorough evaluation of existing guidelines on the treatment of atopic dermatitis, publications concerning new biologics and JAK inhibitors not yet incorporated into existing guidelines, and expert-based recommendations. It also includes considerations on atopic dermatitis severity, indications for initiating biologic agents and JAK inhibitors, parameters to be considered in the treatment choice, in particular treatment goals, and recommendations for the use, screening and monitoring of these therapies.

【 授权许可】

CC BY-NC-ND